1. Pink Sheet
  2. >>Market Access

Lilly Bars Contract Pharmacies From 340B Discounts Despite HRSA Guidance

 
• By Cathy Kelly

Distribution limits for Cialis prompts concerns among 340B-eligible providers that Lilly will impose similar restrictions for additional products and that other manufacturers may follow suit.

Compliance Business Concept - light bulb with text on blackboard background, female hand with chalk
Compliance With HRSA Guidance Under Dispute

Eli Lilly and Company is challenging 10-year old federal guidance allowing contract pharmacies to receive 340B pricing by implementing a plan that blocks those entities from getting the discounts for Cialis.

The restrictions apply to Cialis (tadalafil) formulations approved specifically for patients with erectile dysfunction. They were announced in a

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Access

More from Pink Sheet

Why Chiesi’s Raxone Faced A Decade-Long Wait For English Funding

 
• By Eliza Slawther

Chiesi’s orphan drug Raxone has secured an English funding recommendation for the treatment of Leber's hereditary optic neuropathy, a decade after the orphan drug was approved for marketing. Chiesi told the Pink Sheet about its “long, and often challenging” road to reimbursement.

Europe Eyes First Therapies For PSC And cALD In Latest EMA Drug Filings

 
• By Neena Brizmohun

Norucholic acid and leriglitazone, for treating primary sclerosing cholangitis and cerebral adrenoleukodystrophy, respectively, are among 12 new drugs that the European Medicines Agency has started to review for potential EU marketing approval.

New Advisory Group To Shape UK’s Simplified Informed Consent Process

 
• By Anabel Costa-Ferreira

Although the UK Health Research Authority’s initial proposal for simplified informed consent was rejected by stakeholders, it has yielded valuable insights into reducing trial burden and widening access